Takeda Chemical Industries, Inc.

Shionogi Company Limited

Kirin Beer Kabushiki Kaisha

Other

Kyoto University

Astellas Pharma Gmbh

Research Development Corporation

Shuh Narumiya

Masayuki Narisada

Masami Doteuchi

Toru Kita

Atsushi Ichikawa

Nobuaki Takahashi

Masahiko Akamatsu

Fumihiko Watanabe

Akihiro Iwamatsu

Yoshiharu Kimura

Saichi Matsumoto

Hironori Harada

Hisao Hamaguchi

Takuji Mizui

Osamu Hayaishi

Naoto Nakamura

Shimon Sakaguchi

Masami Tsuboshima

Norihisa Mikami

Fumrhio Watanabe

Satoru Ujihara

Guliang Xia

Naganari Ohkura

Provided are a novel compound having CDK8 and/or CDK19 inhibitory activity, and a production method for Tregs. The treatment of T cells with a CDK8 and/or CDK19 inhibitor induces Foxp3 in the T cells. Foxp3T cells can be induced by treating Foxp3T cells with the CDK8 and/or CDK19 inhibitor in vitro. Thus, Tregs can be induced.

Compound, and method for producing regulatory T cells

An objective of the present invention is to provide an activated Rho protein target protein derived from a human and a gene coding for the same. The present invention provides a protein derived from a human and a derivative thereof which has the following characteristics: (1) having activated Rho protein binding activity, (2) having profilin binding activity, (3) the gene coding for the protein being located at q31.2 of chromosome 5, and (4) having a molecular weight of about 150 kDa as measured by SDS-PAGE. Respiratory tract hypersensitivity, bronchial asthma, acute myelocytic leukemia (AML) and myelodysplasia syndrome (MDS) can be diagnosed using the nucleotide sequence coding for this protein.

Rho target protein human mDia and gene encoding same

The object of the present invention is to provide a target protein for the activated Rho protein. The present invention is a protein having the activated Rho protein binding activity and protein kinase activity, or derivatives thereof. The molecular weight of the protein is about 160 kDa as measured by SDS-PAGE. The protein kinase activity of the protein is enhanced when it binds to the activated Rho protein.

Rho target protein kinase p160

Disclosed are (1) a protein capable of receiving PGE, (2) a recombinant DNA coding for said protein, (3) a vector having said DNA, (4) a transformant carrying said vector, and (5) a method for producing said protein wherein said transformant is cultured in a culture medium, the protein being useful not only in cloning other PGE receptor genes, clarifying the structure of PGE receptors and elucidating the function of PGE, but also in searching for PGE antagonists and agonists and so on.

Prostaglandin E receptors, their DNA and production

Phenolic thioethers of the formula: ##STR1## wherein R is a hydrogen atom or a protective group for carboxyl, X is a straight or branched C.sub.4 -C.sub.15 alkylene group, a straight or branched C.sub.1 -C.sub.15 alkylene group having a phenylene group or a straight or branched C.sub.2 -C.sub.15 alkenylene group, and their salts, which inhibit the denaturation of low density lipoproteins (LDL) and the incorporation of LDL by macrophages and are useful as anti-arteriosclerosis agents.

Phenolic thioethers, and their production and use

(Di-tert-butylhydroxyphenyl)thio derivatives of the formula: ##STR1## wherein R is cyano, carbamoyl, or 5-tetrazolyl; n is an integer of 2 to 6; provided that when R is cyano, n is not 2; or a pharmaceutically acceptable salt thereof; useful in treating arterioschlerosis, ulcer, inflammation, allergy, or the like.

(Di-tert-butylhydroxyphenyl)thio derivatives and antiarterioschlerosis

Permeability characterized in that the carboxy group at 1-position of the prostaglandin is combined with a cell membrane permeable substance having hydroxy group or amino group through the intermediation of an ester bond to the hydroxy group or an amide bond to the amino group are novel and have improved cell membrane permeability.

Prostaglandin derivatives

Growing community of inventors

Kyoto, Japan

Shuh Narumiya